Other Events ·
Veraxa Biotech AG shareholders approved amendments to the Articles of Association at an Extraordinary General Meeting…
VRXAVeraxa Biotech AG - Post de-SPAC
Veraxa Biotech AG shareholders approved amendments to the Articles of Association at an Extraordinary General Meeting on July 24, 2026. Key changes include the introduction of conditional share capital for shareholder options and warrants, the implementation of a capital band through December 31, 2030, and increasing the maximum Board of Directors size from five to seven. The company also announced the appointment of Carl von Halem as Interim CFO and Christoph Erkel, Ph.D., as Chief Scientific Officer. Additionally, the company initiated cell line development for its BiTAC-TCE technology platform. Veraxa Biotech AG is a biotechnology company developing next-generation cancer therapeutics.